Google
IXHL — INCANNEX HEALTHCARE LTD ADR (Healthcare >> Drug Manufacturers - Specialty & Generic)
IXHL FAQ
What is IXHL's ROE?
INCANNEX HEALTHCARE LTD ADR reports a Return on Equity (ROE) of -69.63%.
What is IXHL's dividend yield?
INCANNEX HEALTHCARE LTD ADR offers a dividend yield of 0.00%.
What is IXHL's Deepscope Quality Score?
Deepscope rates IXHL's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IXHL?
Deepscope's AI Timing Score for IXHL is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IXHL belong to?
INCANNEX HEALTHCARE LTD ADR is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 3.09
Price
0.03
(0.98%)
Day Change
|
|
|---|
IXHL, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.09 |
| PBV / Sector |
0.49 / 2.65
GREAT
|
| Earning Per Share | -4.42 |
| PE / Sector |
N/A / 22.84
|
| PEG or PE/Growth / Sector |
N/A / 0.11
|
| Average 1M Daily Value |
0.87 M
GREAT
|
| Average 1W Daily Value |
0.56 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:27 |
| Symbol | IXHL |
| Name | INCANNEX HEALTHCARE LTD ADR |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 11.96 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 36.59 / 9,638.91 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 8 Century Circuit, Sydney, NSW, Australia, 2153
Phone: 61 4 0984 0786
Website: https://www.incannex.com
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
